公告本公司115年股東常會改選董事當選名單

OBIGEN PHARMA INC. Announces Full Enrollment of Two Confirmatory Phase III Pivotal Trials of OBI-858 in Taiwan

OBIGEN PHARMA INC. to Present Phase II Clinical Data in E-Poster Presentation of Novel Long-Acting Botulinum Toxin OBI-858 at AMWC 2026

OBIGEN PHARMA INC. Announces U.S. FDA Acceptance of Phase II IND for OBI-858 in Aesthetic Glabellar Lines

OBIGEN PHARMA INC. Launches Phase III Clinical Trial of World’s First 760 kDa Long-Acting Botulinum Toxin OBI-858 in Taiwan

OBIGEN Announces Taiwan Emerging Board Listing to Accelerate Global Botulinum Toxin Expansion

OBIGEN Pharma’s Phase II Clinical Trial Results for Novel 760 kDa Botulinum Toxin Published in International Journal Dermatology and Therapy

OBIGEN’s Self-Developed Taiwanese Novel Botulinum Toxin for Aesthetics Succeeds in Phase 2 Trial

OBIGEN PHARMA has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

OBIGEN Pharma Appoints New CEO to Lead IPO Growth